Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (NCT04881760)
The SUSTAIN-6 cardiovascular outcomes trial established that semaglutide also reduces the risk of major adverse cardiovascular events (MACE) by 26% relative to placebo in high-risk patients a finding that fundamentally changed the treatment landscape for metabolic disease
Its essential to be patient during your treatment period and understand this isnt a quick fix or substitution for a healthy lifestyle
To receive the prescription, you will need an in-person or virtual consultation with Dr
This hormone signals your brain that you are satisfied, reducing hunger and appetite drive
It has been shown to decrease homocysteine levels which reduces our risk of developing heart attacks, strokes or dementia
US$ 25.81
US$ 29.66
US$ 22.91
